Danicamtiv Increases Myosin Recruitment and Alters Cross-Bridge Cycling in Cardiac Muscle.
Kristina B KooikerSaffie E MohranKyrah L TurnerWeikang MaAmy MartinsonGalina FlintLin QiChengqian GaoYahan ZhengTimothy S McMillenChristian J MandryckyMax Mahoney-SchaeferJeremy C FreemanElijah Gabriela Costales ArenasAn-Yu TuThomas C IrvingMichael A GeevesBertrand C W TannerMichael RegnierJennifer M DavisFarid Mousavi-HaramiPublished in: Circulation research (2023)
As demonstrated by the detailed studies of Danicamtiv, increasing myosin recruitment and altering cross-bridge cycling are 2 mechanisms to increase force and calcium sensitivity in cardiac muscle. Myosin activators such as Danicamtiv can treat the causative hypocontractile phenotype in genetic dilated cardiomyopathy.